EI
BNTC icon

EAM Investors’s Benitec Biopharma BNTC Stock Holding History

EAM Investors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,809
Closed -$442K – 268
2025
Q2 		$442K Sell
37,809
-1,521
-4% -$21.3K 0.07% 216
2025
Q1 		$512K Buy
+39,330
New +$476K 0.09% 224

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

EAM Investors's BNTC Position: Q3 2025 in Review

EAM Investors sold out of Benitec Biopharma (BNTC) in Q3 2025, closing a stake of 37,809 shares — an estimated $442K sold.

EAM Investors first reported a position in BNTC in Q1 2025 and held it in 2 quarters. The position peaked at $512K in Q1 2025. 56 funds tracked by Wall St. Rank hold BNTC as of Q3 2025.

  • EAM Investors reported no remaining Benitec Biopharma position as of Q3 2025 after selling out during the quarter.
  • EAM Investors sold 37,809 Benitec Biopharma shares in Q3 2025, an estimated $442K.
  • EAM Investors first reported a position in Benitec Biopharma in Q1 2025 and held it in 2 quarters.
  • EAM Investors's Benitec Biopharma position peaked at $512K in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.